Skip to content
Menu

Lake Street Maintains Buy on Kyntra Bio, Lowers Price Target to $8

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Lake Street analyst Daniel Brims maintains Kyntra Bio (NASDAQ:KYNB) with a Buy and lowers the price target from $41 to $8.

Lake Street analyst Daniel Brims maintains Kyntra Bio (NASDAQ:KYNB) with a Buy and lowers the price target from $41 to $8.

Read at benzinga.com